FN Media Group Presents Microsmallcap.com Market Commentary
New York, NY – May 13, 2021 – Psychedelics are quietly being used in clinical settings on small numbers of patients, but they are moving quickly toward medical approval. The FDA recently approved large-scale human trials to determine whether MDMA and other psychedelics warrant the agency’s approval for treatment. The result is a budding industry of psychedelic research and innovation that is quickly moving these alternative treatments to the forefront of the medical community’s attention. For companies like Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), psychedelics are the lynchpin of a strategy to treat the rare and difficult diseases that currently have unmet needs. Then, there’s Compass Pathways (NASDAQ:CMPS), which uses psilocybin for treating depression, and is conducting a study using guided psilocybin as a treatment for drug-resistant depression. Biotechnology company Cybin Inc. (NEO:CYBN) (OTC:CLXPF) is continuing to build out its development and clinical operations for psychedelic therapeutics in Europe and the US, while multinational pharmaceutical companies like Merck & Co. (NYSE:MRK) are introducing partnerships to fund research into psychedelics. Even big pharma companies like Eli Lilly & Company (NYSE:LLY), which has yet to dive into psychedelics, are uniquely positioned to develop and bring to market new treatments using psychedelics that target serotonin using their expertise in SSRIs.
How Tryp Therapeutics Is Developing New Solutions to Old Problems
The positive effects of psychedelics are now being tested and used for medicinal purposes, as doctors and patients look for more effective alternatives to the traditional pharmaceuticals currently available on the market. Tryp Therapeutics, a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan (rare) diseases and other diseases with high unmet medical needs, is forging ahead by submitting a provisional patent to improve how psychedelics are administered across a broad spectrum of indications. The company is using novel methods for the formulation, delivery, and dosing of psychedelics resulting in a potential reduction in the time spent by patients in the dissociative state. Tryp Therapeutics is developing this technology and these methods for a wide variety of conditions, and their efforts aim to enhance the effectiveness of psychedelics and to further differentiate Tryp’s intellectual property position. The patent, if approved, would protect the company’s differentiated methods for dosing, delivering, and administrating its psilocybin-based therapies.
Tryp Therapeutics’ psilocybin-for-neuropsychiatric disorders program aims to develop synthetic psilocybin as a new class of drug for the treatment of neuro-psychiatric-based disorders that may be difficult to treat, or do not have their medical needs met. It is also developing TRP-1001, which is an oral version of razoxane, a drug used in the treatment of soft tissue sarcoma. This is a treatment for a rare and diverse group of tumors that account for 1% of all cancers in adults and 7% in children. The rareness of the disease means that Tryp believes that TRP-1001 should qualify for Orphan Drug Status.
Tryp Therapeutics is advancing medical science through these projects with a strong team of world class scientific advisors. Robin Carhart-Harris, Ph.D., Joel Castellanos, M.D., Rachel Wevrick, Ph.D., Derek Ott, M.D., and Wiliam Schmidt, Ph.D. compose Tryp’s Scientific Advisory Board, bringing their vast wealth of experience and expertise to the company’s development of drugs for pain indications. Their appointments to Tryp’s Scientific Advisory Board have strengthened the company’s focus and progress across its portfolio of projects.
The company has also ensured that investors have complete access to shares on the open market by commencing trading on the OTCQB Venture Market and becoming DTC eligible in April. This announcement marked the beginning of expanded access for millions of prospective investors in the US. Private investors have been active with the company this year as well, with Marc Lustig, founder and former Chairman of Origin House, leading a $2 million strategic financing deal in February 2021.
Major Players Are Getting in on the Action
Merck & Co. (NYSE:MRK) recently announced their partnership with Novamind to make it a key research site for a clinical trial that will focus on treatment-resistant depression using MDMA and ketamine. The Phase 2 trial will research a compound developed by Merck called MK-1942 to test the currently undescribed molecule for efficacy and safety, with the goal of using it alongside antidepressants for the treatment of treatment-resistant depression.
Cybin Inc. (NEO:CYBN) (OTC:CLXPF) is expanding its buildout for development and operations in Europe and the US, as the company focused on progressing psychedelic therapeutics forges ahead in advancing its mission of improving mental healthcare through therapeutic development programs and innovative drug delivery systems. The company also recently appointed Alexander Belser, PhD. as Chief Clinical Officer, and Aaron Bartlone as Chief Operating Officer.
Compass Pathways (NASDAQ:CMPS), a psychedelics-inspired medicine developer, will release Phase 2b trial data for its leading drug candidate, COMP 360, later in 2021. The release of the clinical trial data will be the first for a psychedelic-inspired drug. The company uses psilocybin to treat depression, and their study of a guided approach to treating depression with the drug is a commitment to their psychedelics-inspired approach that the market is so excited about.
Eli Lilly & Company (NYSE:LLY) is already one of the largest manufacturers of psychiatric medications, with a profitable portfolio of traditional treatments. The company’s expertise developing drugs that treat depression using SSRIs will give it a head start in the psychedelic and psychedelic-inspired drug development ramping up now. Investors are looking for established drug makers to step into the innovative spaces like psychedelics and make continued progress in the treatment of diseases that currently have unmet treatment needs.
The Trailblazing Has Already Begun
For more information about Tryp Therapeutics, please click here.
Disclaimer: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Tryp Therapeutics.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
FN Media Group, LLC